ErbB1 (EGFR) and ErbB2 (HER2/Neu) drive oncogenesis in many human malignancies; ErbB2 overexpression, due to gene amplification and/or increased transcription, drives oncogenesis in up to a quarter of human breast cancer patients and specifies poor overall patient survival [4,5]. This evidence concerns the gene EGFR and breast cancer.